Watching Biohaven; Shares Trade Higher As Co Releases Presentation, Including Pharmacodynamic Updates For BHV-1300, The Co's Bispecific IgG Degrader, Showing Greater Than 90% Reductions In IgG After Repeat Dosing And Is Incorporated Herein By Reference
Benzinga Newsdesk - Sep 27, 2023, 9:50AM